These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34369083)

  • 1. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.
    Yang Z; Liang SQ; Saliakoura M; Yang H; Vassella E; Konstantinidou G; Tschan M; Hegedüs B; Zhao L; Gao Y; Xu D; Deng H; Marti TM; Kocher GJ; Wang W; Schmid RA; Peng RW
    EMBO Mol Med; 2021 Sep; 13(9):e13193. PubMed ID: 34369083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for
    Yang Z; Liang SQ; Yang H; Xu D; Bruggmann R; Gao Y; Deng H; Berezowska S; Hall SRR; Marti TM; Kocher GJ; Zhou Q; Schmid RA; Peng RW
    Cancer Res; 2021 Jun; 81(11):3121-3133. PubMed ID: 33685992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combinatorial strategy for treating KRAS-mutant lung cancer.
    Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
    Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
    Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
    Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
    Pang X; Liu M
    Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kinase PLK1 promotes the development of
    Kong Y; Allison DB; Zhang Q; He D; Li Y; Mao F; Li C; Li Z; Zhang Y; Wang J; Wang C; Brainson CF; Liu X
    Sci Signal; 2022 Oct; 15(754):eabj4009. PubMed ID: 36194647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
    Narvaez AJ; Ber S; Crooks A; Emery A; Hardwick B; Guarino Almeida E; Huggins DJ; Perera D; Roberts-Thomson M; Azzarelli R; Hood FE; Prior IA; Walker DW; Boyce R; Boyle RG; Barker SP; Torrance CJ; McKenzie GJ; Venkitaraman AR
    Cell Chem Biol; 2017 Aug; 24(8):1017-1028.e7. PubMed ID: 28807782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
    Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ
    Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE; Kim TS; Kim BY; Lee KS
    Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.
    Yang Z; Liang SQ; Zhao L; Yang H; Marti TM; Hegedüs B; Gao Y; Zheng B; Chen C; Wang W; Dorn P; Kocher GJ; Schmid RA; Peng RW
    J Exp Clin Cancer Res; 2022 Jan; 41(1):25. PubMed ID: 35039048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 16. Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.
    Bowman BM; Sebolt KA; Hoff BA; Boes JL; Daniels DL; Heist KA; Galbán CJ; Patel RM; Zhang J; Beer DG; Ross BD; Rehemtulla A; Galbán S
    Sci Signal; 2015 Jan; 8(361):ra9. PubMed ID: 25628462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
    Quintanal-Villalonga A; Molina-Pinelo S; Cirauqui C; Ojeda-Márquez L; Marrugal Á; Suarez R; Conde E; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
    J Thorac Oncol; 2019 Apr; 14(4):641-655. PubMed ID: 30639621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1).
    Luo P; Yan H; Du J; Chen X; Shao J; Zhang Y; Xu Z; Jin Y; Lin N; Yang B; He Q
    Autophagy; 2021 Oct; 17(10):3221-3237. PubMed ID: 33315519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.